BioAxone is poised to revolutionize the way spinal cord injury is treated. The company is currently privately financed and has grown a strong pipeline from non-dilutive grant financing.
BioAxone is building on the following value:
- Experienced management
- Well balanced development team
- Validated science
- Over 14 issued patents (US and Global)
- Key partnerships to build the business
- Understanding of translational medicine to bring new drugs forward to clinical testing
- Successful NIH/SBIR funding and a strong pipeline
For direct information on investment opportunities, please contact:
Dr. Lisa McKerracher
Chief Executive Officer, BioAxone
(617) 401 3115
info@bioaxonebio.com